Labcorp Launches First FDA-Cleared Blood Test for Alzheimer's Detection

Key Facts

In a move reflecting the rapid evolution of the medical diagnostics sector, Labcorp announced it will offer the Elecsys pTau-217 test, the first and only FDA-cleared single-biomarker blood test for Alzheimer's pathology. The test is designed to identify amyloid pathology in patients aged 55 and older showing signs of cognitive decline. This launch provides a non-invasive method for clinicians to rule in or rule out Alzheimer's pathology in both primary and specialty care settings, addressing a critical need for early and accessible diagnosis.

This launch strengthens Labcorp's competitive position in the laboratory services market, as the new test adds to a portfolio that already supports a vast majority of FDA-approved therapeutic products. According to market data, Labcorp's stock (LH) closed at $336.34 on August 21, 2026, with a daily high of $336.9 and a low of $330.9, indicating steady performance prior to this strategic announcement.

Operationally, making the Elecsys pTau-217 test available nationwide expands access to innovative blood-based testing, which may impact the volume of tests the company performs annually. With the stock price at $336.34 (close of August 21, 2026), investors will be watching how this exclusive FDA clearance influences future revenue in the neurological diagnostics segment, particularly as demand for early dementia detection solutions grows.